Financial Post
EN
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia SAN JOSE, Calif., March 23, 2026 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower urinary tract symptoms (LUTS), which […]
Read original on financialpost.com ↗Positive for markets
Sentiment score: +72/100
Moderate impact
Medium-term (weeks)
WHAT THIS MEANS
PROCEPT BioRobotics' Aquablation therapy received an upgraded recommendation from the European Association of Urology guidelines, moving to a 'Strong Surgical Recommendation' for benign prostatic hyperplasia treatment. This reflects accumulating clinical evidence supporting the technology's efficacy in European markets.
AI CONFIDENCE
75% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↑
PRCT
PRCTStock
Expected to rise
Upgraded EAU guideline recommendation increases clinical credibility and potential adoption in European markets, supporting revenue growth trajectory for Aquablation therapy
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
PRCT shows medium-term upside potential from guideline validation supporting market expansion. Monitor for Q2 2026 earnings guidance updates and European adoption metrics; guideline upgrades typically drive adoption 2-4 quarters post-announcement.
KEY SIGNALS
SECTORS INVOLVED
Analysis generated on Mar 23, 2026 at 11:07 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
BNN Bloomberg